Shares in big vaccine producers have slumped since Donald Trump asked Robert F. Kennedy (RFK) Jr. to lead the Department of Health and Human Services, says The New York Times. Kennedy, known for his “divisive” views on public health, including “scepticism” about vaccines (as well as pesticides and water fluoridation) is to lead “a huge department… whose regulations affect America’s food and medicine choices”.
How could RFK Jr impact the US healthcare industry?
Installing RFK Jr in an official administration role “may be difficult”, as his anti-vax views have been so extreme that they led to bans on YouTube and Instagram, says Robert Cyran on Breakingviews. That “might preclude confirmation even in a Republican-led Senate”.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
However, even if he only ends up serving as a senior advisor, it would still give him “plenty of scope to target the pharmaceutical and related industries”. While RFK has said in interviews that “he wouldn’t take away anyone’s vaccines”, he reportedly wants to remove product liability protection from vaccines, a step that might have a “similarly harmful effect”.
Whatever role Kennedy eventually plays, even his presence within the administration could “erode public trust” in vaccines, “put up roadblocks to the approval of new vaccines and prevent the CDC from recommending any vaccines that make it through the approval process”, says Morningstar’s Karen Andersen. This, in turn, could mean that certain US states could “waver” in support of broad mandates for childhood vaccines. Still, any reduction in projected US vaccine sales would not be “long-lasting”, and so this should not provide “a significant hit” to drug companies’ valuations.
The industry hopes that RFK’s influence may be cancelled out by other “smart people” advising Trump, say Ian Johnston and Oliver Barnes in the Financial Times. They could restrain RFK, while there may be increased benefits from the stockpiling of certain vaccines for defence purposes.
Vivek Ramaswamy, appointed alongside Elon Musk to oversee a state efficiency drive, has also been a big fan of reducing red tape in the drug approval process, accusing the FDA of erecting “unnecessary barriers to innovation”.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Jim O’Neill on nearly 25 years of the BRICSJim O’Neill, who coined the acronym BRICS in 2001, tells MoneyWeek how the group is progressing
-
Build or innovate? How to solve the productivity puzzleOpinion There are two main schools of thought when it comes to solving the productivity puzzle, says David C. Stevenson
-
Jim O’Neill on nearly 25 years of the BRICS
Jim O’Neill, who coined the acronym BRICS in 2001, tells MoneyWeek how the group is progressing
-
Build or innovate? How to solve the productivity puzzle
Opinion There are two main schools of thought when it comes to solving the productivity puzzle, says David C. Stevenson
-
Circle sets a new gold standard for cryptocurrenciesCryptocurrencies have existed in a kind of financial Wild West. No longer – they are entering the mainstream, and US-listed Circle is ideally placed to benefit
-
8 of the best converted industrial properties for saleThe best converted industrial properties for sale – from a Victorian railway station in Norfolk to a Grade II-listed former water tower with views of the River Alde
-
More clouds gather over renewable energy trusts – is there any hope for the sector?The outlook for renewable energy trusts has gone from bad to worse this year, with the industry being caught in a 'perfect storm'
-
Should ISA investors be forced to hold UK shares?The UK government would like ISA investors to hold more UK stocks – but many of us are already overexposed
-
Why Scotland's proposed government bonds are a terrible investmentOpinion Politicians in Scotland pushing for “kilts” think it will strengthen the case for independence and boost financial credibility. It's more likely to backfire
-
How Germany became the new sick man of EuropeFriedrich Merz, Germany's Keir Starmer, seems unable to tackle the deep-seated economic problems the country is facing. What happens next?
